Temozolomide Chronotherapy in Glioma: A Systematic Review

Outcomes for patients with high-grade glioma remain poor. Temozolomide (TMZ) is the only drug approved for first-line treatment of glioblastoma multiforme, the most aggressive form of glioma. Chronotherapy highlights the potential benefit of timed TMZ administration. This is based on pre-clinical st...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jason L., Alshamsan, Bader, Ng, Terry L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955138/
https://www.ncbi.nlm.nih.gov/pubmed/36826108
http://dx.doi.org/10.3390/curroncol30020147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955138/
https://www.ncbi.nlm.nih.gov/pubmed/36826108
http://dx.doi.org/10.3390/curroncol30020147

Ejemplares similares